Tejas Savant
Stock Analyst at Morgan Stanley
(2.22)
# 2,676
Out of 4,876 analysts
235
Total ratings
40.88%
Success rate
-4.37%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $9 → $7 | $3.62 | +93.37% | 9 | May 28, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $26 → $18 | $11.52 | +56.32% | 14 | May 19, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $136 → $100 | $94.74 | +5.55% | 8 | May 12, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $60 → $65 | $67.95 | -4.34% | 3 | May 9, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $77 → $65 | $65.61 | -0.93% | 9 | May 5, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $7.53 | -7.04% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $11.89 | -24.31% | 12 | May 5, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $17 → $10 | $7.34 | +36.24% | 13 | May 1, 2025 | |
| AVTR Avantor | Downgrades: Equal-Weight | $25 → $15 | $13.71 | +9.45% | 17 | Apr 28, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $2.43 | +106.19% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $48.00 | -58.33% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $169.02 | +9.45% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $158.65 | +57.58% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $413.14 | +64.11% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $24.84 | -7.39% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $27.44 | +2.04% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $5.27 | +298.86% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.29 | +55.04% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $1.35 | +123.05% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $9.83 | +306.92% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.78 | +666.68% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.08 | +224.68% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.50 | -21.43% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $6.38 | -21.63% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.14 | +367.29% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $51.63 | +41.40% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $151.45 | +65.07% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.27 | +1,771.26% | 5 | May 12, 2022 |
Cytek Biosciences
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $3.62
Upside: +93.37%
10x Genomics
May 19, 2025
Maintains: Overweight
Price Target: $26 → $18
Current: $11.52
Upside: +56.32%
Illumina
May 12, 2025
Maintains: Equal-Weight
Price Target: $136 → $100
Current: $94.74
Upside: +5.55%
Tempus AI
May 9, 2025
Maintains: Overweight
Price Target: $60 → $65
Current: $67.95
Upside: -4.34%
Hologic
May 5, 2025
Maintains: Equal-Weight
Price Target: $77 → $65
Current: $65.61
Upside: -0.93%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $7.53
Upside: -7.04%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $11.89
Upside: -24.31%
NeoGenomics
May 1, 2025
Maintains: Equal-Weight
Price Target: $17 → $10
Current: $7.34
Upside: +36.24%
Avantor
Apr 28, 2025
Downgrades: Equal-Weight
Price Target: $25 → $15
Current: $13.71
Upside: +9.45%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.43
Upside: +106.19%
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $48.00
Upside: -58.33%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $169.02
Upside: +9.45%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $158.65
Upside: +57.58%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $413.14
Upside: +64.11%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $24.84
Upside: -7.39%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $27.44
Upside: +2.04%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $5.27
Upside: +298.86%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.29
Upside: +55.04%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $1.35
Upside: +123.05%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $9.83
Upside: +306.92%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.78
Upside: +666.68%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.08
Upside: +224.68%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.50
Upside: -21.43%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $6.38
Upside: -21.63%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.14
Upside: +367.29%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $51.63
Upside: +41.40%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $151.45
Upside: +65.07%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.27
Upside: +1,771.26%